Canadian Prostate Brachytherapy in 2012

Authors

  • Mira Keyes Prostate Brachytherapy Program, British Columbia Cancer Agency, Vancouver, BC
  • Juanita Crook Prostate Brachytherapy Program, British Columbia Cancer Agency, Kelowna BC and Department of Radiation Oncology Princes Margaret Hospital Toronto ON
  • W. James Morris Prostate Brachytherapy Program, British Columbia Cancer Agency, Vancouver, BC
  • Gerard Morton Department of Radiation Oncology, Odette Cancer Center, Toronto ON
  • Tom Pickles Prostate Brachytherapy Program, British Columbia Cancer Agency, Vancouver, BC
  • Nawaid Usmani Department of Radiation Oncology, Cross Cancer Institute, Edmonton, AB
  • Eric Vigneault Quebec University Hospital l'Hotel-Dieu de Quebec, Quebec City QC

DOI:

https://doi.org/10.5489/cuaj.218

Keywords:

Prostate Brachytherapy, PSA outcomes, toxicity

Abstract

Prostate brachytherapy can be used as a monotherapy for low- and intermediate-risk patients or in combination with external beam radiation therapy (EBRT) as a form of dose escalation for selected intermediate- and high-risk patients. Prostate brachytherapy with either permanent implants (low dose rate [LDR]) or temporary implants (high dose rate [HDR]) is emerging as the most effective radiation treatment for prostate cancer. Several large Canadian brachytherapy programs were established in the mid- to late-1990s. Prostate brachytherapy is offered in British Columbia, Alberta, Manitoba, Ontario, Quebec and New Brunswick. We anticipate the need for brachytherapy services in Canada will significantly increase in the near future. In this review, we summarize brachytherapy programs across Canada, contemporary eligibility criteria for the procedure, toxicity and prostate-specific antigen recurrence free survival (PRFS), as published from Canadian institutions for both LDR and HDR brachytherapy.

Downloads

Download data is not yet available.

Downloads

Published

2013-02-20

How to Cite

Keyes, M., Crook, J., Morris, W. J., Morton, G., Pickles, T., Usmani, N., & Vigneault, E. (2013). Canadian Prostate Brachytherapy in 2012. Canadian Urological Association Journal, 7(1-2), 51–58. https://doi.org/10.5489/cuaj.218

Issue

Vol. 7 No. 1-2 (2013): CUAJ February

Section

Review

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.